1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Non-cystic Fibrosis Bronchiectasis (NCFB)- Epidemiology Forecast to 2030

Non-cystic Fibrosis Bronchiectasis (NCFB)- Epidemiology Forecast to 2030

  • May 2020
  • 100 pages
  • ID: 5897613
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Non-cystic fibrosis bronchiectasis (NCFB) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Non-cystic fibrosis bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Non-cystic fibrosis bronchiectasis (NCFB) Understanding
Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree which leads to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are daily cough, daily sputum production, and frequent respiratory infections. In patients without cystic fibrosis, the condition is known as non-cystic fibrosis bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis Epidemiology Perspective
The Non-cystic fibrosis bronchiectasis epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The Non-cystic fibrosis bronchiectasis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-cystic fibrosis bronchiectasis epidemiology is segmented by Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-cystic fibrosis bronchiectasis Detailed Epidemiology Segmentation
The Non-cystic fibrosis bronchiectasis epidemiology covered in the report provides historical as well as forecasted epidemiology {Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB} scenario of Non-cystic fibrosis bronchiectasis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2030.
The Non-cystic fibrosis bronchiectasis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
• The Non-cystic fibrosis bronchiectasis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Non-cystic fibrosis bronchiectasis Epidemiology Report and Model provide an overview of the risk factors and global trends of Non-cystic fibrosis bronchiectasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Non-cystic fibrosis bronchiectasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Non-cystic fibrosis bronchiectasis
• The report provides the segmentation of the Non-cystic fibrosis bronchiectasis epidemiology by Etiology associated with NCFB in 7MM
• The report provides the segmentation of the Non-cystic fibrosis bronchiectasis epidemiology by Microbiology of NCFB in 7MM

Report Highlights
• 11-Year Forecast of Non-cystic fibrosis bronchiectasis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Non-cystic fibrosis bronchiectasis
• Prevalent Cases according to segmentation: Etiology, Microbiology, Severity and Gender
• Diagnosed cases of NCFB
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-cystic fibrosis bronchiectasis?
• What are the key findings pertaining to the Non-cystic fibrosis bronchiectasis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Non-cystic fibrosis bronchiectasis across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Non-cystic fibrosis bronchiectasis?
• What are the current available treatments of Non-cystic fibrosis bronchiectasis?

Reasons to buy
The Non-cystic fibrosis bronchiectasis Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Non-cystic fibrosis bronchiectasis market
• Quantify patient populations in the global Non-cystic fibrosis bronchiectasis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-cystic fibrosis bronchiectasis therapeutics in each of the markets covered
• Understand the magnitude of Non-cystic fibrosis bronchiectasis population by its Sub-Types
• The Non-cystic fibrosis bronchiectasis epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Non-cystic fibrosis bronchiectasis Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden

• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Although NCFB was once a very uncommon diagnosis, in the last two decades, its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice.
The precise prevalence of NCFB is difficult to determine because estimates vary among populations, but studies report a prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.

Bronchiectasis may be caused by several factors, including previous severe respiratory infections (e.g., bacterial pneumonia or tuberculosis), allergic bronchopulmonary aspergillosis (ABPA), impairment of ciliary clearance (e.g., primary ciliary dyskinesia), and primary or secondary immunodeficiency, and it may also be associated with other diseases, such as chronic obstructive pulmonary disease (COPD) and severe asthma. Although the etiology of bronchiectasis is unknown in many cases, there is growing awareness regarding the importance of COPD as an underlying cause.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on